GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » DOD Biotech PCL (BKK:DOD-R) » Definitions » Debt-to-Revenue

DOD Biotech PCL (BKK:DOD-R) Debt-to-Revenue : 0.07 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is DOD Biotech PCL Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

DOD Biotech PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ฿45.0 Mil. DOD Biotech PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ฿0.1 Mil. DOD Biotech PCL's annualized Revenue for the quarter that ended in Mar. 2025 was ฿684.3 Mil. DOD Biotech PCL's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.07.


DOD Biotech PCL Debt-to-Revenue Historical Data

The historical data trend for DOD Biotech PCL's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DOD Biotech PCL Debt-to-Revenue Chart

DOD Biotech PCL Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.18 0.43 0.25 0.07

DOD Biotech PCL Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.23 0.09 0.08 0.07

Competitive Comparison of DOD Biotech PCL's Debt-to-Revenue

For the Packaged Foods subindustry, DOD Biotech PCL's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DOD Biotech PCL's Debt-to-Revenue Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where DOD Biotech PCL's Debt-to-Revenue falls into.


;
;

DOD Biotech PCL Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

DOD Biotech PCL's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(45.77 + 0.286) / 645.385
=0.07

DOD Biotech PCL's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(44.955 + 0.111) / 684.264
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.


DOD Biotech PCL Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of DOD Biotech PCL's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


DOD Biotech PCL Business Description

Traded in Other Exchanges
Address
No. 111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The company is organized into business units based on its products and services and has reportable segments as; Supplementary business, Manufacturing cosmetic business, Manufacturing extraction business, and others. A majority of its revenue is generated from the Supplementary business which manufactures and sells dietary supplements in the form of capsules, tablets, soft gels, gummies, probiotics, shot drinks, and others. Geographically, the company operates only in Thailand.

DOD Biotech PCL Headlines

No Headlines